ZNRF4

Across TCGA pan-cancer cohorts, ZNRF4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNRF4 data layer compared with 17 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNRF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNRF4 expression acts as an unfavorable survival marker.

LUAD, CESC, and LIHC are the cancer types where ZNRF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.171	0.714	<.001	30	view →
CESC	OS	Median	All	0.104	0.587	.016	18	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SARC	DFS	Median	All	0.210	0.612	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNRF4–LUAD (OS)

Open the LUAD breakdown →